UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
AstraZeneca is making a big push into the weight-loss drug market, striking an exclusive licence agreement with a Chinese company for an obesity and type 2 diabetes pill that is in early stage development.
Britain’s biggest drugmaker said it had agreed a deal with Eccogene, based in Shanghai, for an experimental drug named ECC5004 that would also treat other cardiometabolic conditions such as heart disease and stroke. Eccogene will receive up to $2bn under the terms of the deal.
About Author
More Stories
Nigeria sues crypto giant Binance for $81.5bn in economic losses and back tax
Chinese fishing fleets using North Korean forced labour in potential breach of sanctions, report claims
#AltGov: the secret network of federal workers resisting Doge from the inside